FDA.reportPublic FDA data

Xembify 20 % (4 GM in 20 ML) Injection

RxCUI
2196491
RxNorm name
Xembify 20 % (4 GM in 20 ML) Injection
Display name
Xembify 20 % (4 GM in 20 ML) Injection
Full name
Xembify 20 % (4 GM in 20 ML) Injection
Term type
PSN
Status
DailyMed mapping
Updated
2026-06-04 23:39:08

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
125683Xembifyimmune globulin subcutaneous, human-klhw351(a)Rx2026-06-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

DailyMed RxNorm Mappings#

Set ID, RxNorm string, TTY table
Set IDRxNorm stringTTYSPL versionLabelEffective
8c174b11-a061-412e-a3b2-7bf7e1adaaceXembify 20 % (4 GM in 20 ML) InjectionPSN12These highlights do not include all the information needed to use XEMBIFY safely and effectively. See full prescribing information for XEMBIFY. XEMBIFY (immune globulin subcutaneous, human – klhw) 20% solution Initial U.S. Approval: 201920250317
8c174b11-a061-412e-a3b2-7bf7e1adaace20 ML immune globulin subcutaneous (human) - klhw 200 MG/ML Injection [Xembify]SBD12These highlights do not include all the information needed to use XEMBIFY safely and effectively. See full prescribing information for XEMBIFY. XEMBIFY (immune globulin subcutaneous, human – klhw) 20% solution Initial U.S. Approval: 201920250317
8c174b11-a061-412e-a3b2-7bf7e1adaace20 ML Xembify 200 MG/ML InjectionSY12These highlights do not include all the information needed to use XEMBIFY safely and effectively. See full prescribing information for XEMBIFY. XEMBIFY (immune globulin subcutaneous, human – klhw) 20% solution Initial U.S. Approval: 201920250317
8c174b11-a061-412e-a3b2-7bf7e1adaaceXembify 20 % (4 GM per 20 ML) InjectionSY12These highlights do not include all the information needed to use XEMBIFY safely and effectively. See full prescribing information for XEMBIFY. XEMBIFY (immune globulin subcutaneous, human – klhw) 20% solution Initial U.S. Approval: 201920250317